Ask AI
Obesity Care in Obstetrics and Gynecology

CE / CME

Obesity Management During Women’s Reproductive Years: Expert Insights to Your Clinical Queries

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: October 29, 2025

Expiration: October 28, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020;:1-8.
  2. Driscoll AK, Gregory ECW. Increases in prepregnancy obesity: United States, 2016-2019. NCHS Data Brief. 2020;:1-8.
  3. Amiri M, Ramezani Tehrani F. Potential adverse effects of female and male obesity on fertility: A narrative review. Int J Endocrinol Metab. 2020;18:e101776.
  4. Vyrides AA, El Mahdi E, Giannakou K. Ovulation induction techniques in women with polycystic ovary syndrome. Front Med (Lausanne). 2022;9:982230.
  5. Nadolsky K, Garvey WT, Agarwal M, et al. American Association of Clinical Endocrinology consensus statement: Algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update. Endocr Pract. 2025:S1530-891X(25)00977-2.
  6. Schon S, Spizman J, Stelmak D, et al. A multidisciplinary approach to weight management and reproductive care: A retrospective cohort study on weight loss through personalized and patient-centered care. Reprod Biol Endocrinol. 2025;23:89.
  7. Vasilevski V, Mekonnen A, Peeters A, et al. Healthcare related barriers and enablers for weight management among pregnant women with overweight and obesity: a rapid scoping review. BMC Pregnancy Childbirth. 2025;25:252.
  8. Persson M, Razaz N, Edstedt Bonamy AK, et al. Maternal overweight and obesity and risk of congenital heart defects. J Am Coll Cardiol. 2019;73:44-53.
  9. Gaudet L, Ferraro ZM, Wen SW, et al. Maternal obesity and occurrence of fetal macrosomia: a systematic review and meta-analysis. Biomed Res Int. 2014;2014:640291.
  10. Endres LK, Straub H, McKinney C, et al; Community Child Health Network of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Postpartum weight retention risk factors and relationship to obesity at 1 year. Obstet Gynecol. 2015;125:144-152.
  11. Kramer CK, Ye C, Hanley AJ, et al. Postpartum weight retention and the early evolution of cardiovascular risk over the first 5 years after pregnancy. Cardiovasc Diabetol. 2024;23:101.
  12. Boots CE, Gloff M, Lustik SJ, et al. Addressing weight bias in reproductive medicine: a call to revisit body mass index restrictions for in vitro fertilization treatment. Fertil Steril. 2024;122:204-210.
  13. Centers for Disease Control and Prevention. Adult BMI categories. cdc.gov/bmi/adult-calculator/bmi-categories.html. Accessed October 24, 2025.
  14. Swaleh R, McGuckin T, Myroniuk TW, et al. Using the Edmonton Obesity Staging System in the real world: A feasibility study based on cross-sectional data. CMAJ Open. 2021;9:E1141-E1148.
  15. Dobbie LJ, Coelho C, Crane J, et al. Clinical evaluation of patients living with obesity. Intern Emerg Med. 2023;18:1273-1285.
  16. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13:221-262.
  17. Tucker S, Bramante C, Conroy M, et al. The most undertreated chronic disease: Addressing obesity in primary care settings. Curr Obes Rep. 2021;10:396-408.
  18. Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26-36.
  19. Warhurst S, Georgousopoulou E, Sethna F, et al. Referral practices and treatment of obstructive sleep apnea in pregnancies with obesity. Obes Sci Pract. 2024;10:e574.
  20. Epworth Sleepiness Scale. cdc.gov/niosh/work-hour-training-for-nurses/longhours/mod2/epworth-P.pdf. Accessed October 24, 2025.
  21. The STOP Bang Questionnaire. sleepeducation.org/wp-content/uploads/2023/01/Stop-Bang-Questionnaire.pdf. Accessed October 24, 2025.
  22. Phentermine [prescribing information]. Sellersville, PA: Teva Pharmaceuticals, USA; 2012.
  23. Phentermine and topiramate [prescribing information]. Campbell, CA: Vivus, LLC; 2024.
  24. Xenical [prescribing information]. South San Francisco, CA: Genentech USA, Inc; 2022
  25. Naltrexone hydrochloride and bupropion hydrochloride [prescribing information]. Brentwood, TN: Nalpropion Pharmecaeuticals, LLC; 2024.
  26. Liraglutide [prescribing information]. Plainsboro, NJ: Novo Nordisk, Inc; 2025.
  27. Semaglutide [prescribing information]. Plainsboro, NJ: Novo Nordisk, Inc; 2025.
  28. Tirzepatide [prescribing information]. Indianapolis, IN: Lilly USA, Inc; 2025
  29. Courcoulas AP, Belle SH, Neiberg RH, et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: A randomized clinical trial. JAMA Surg. 2015;150:931-40.
  30. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577-85.
  31. Luo Y, Haddad RA, Ontan MS, et al. Impact of diabetes on weight loss outcomes after bariatric surgery: experience from 5-year follow-up of Michigan Bariatric Surgery Cohort. Clin Endocrinol (Oxf). 2023;99:285-295.
  32. Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: A committee opinion. Fertil Steril. 2021;116:1266-1285.
  33. Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: A clinical practice guideline. CMAJ. 2020;192:E875-E891.
  34. Hazlehurst JM, Singh P, Bhogal G, et al. How to manage weight loss in women with obesity and PCOS seeking fertility? Clin Endocrinol (Oxf). 2022;97:208-216.
  35. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108:2447-2469.
  36. Duah J, Seifer DB. Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review. Reprod Biol Endocrinol. 2025;23:2.
  37. Elkind-Hirsch KE, Chappell N, Shaler D, et al. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil Steril. 2022;118:371-381.
  38. Chen H, Lei X, Yang Z, et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Reprod Biol Endocrinol. 2025;23:108.
  39. Topiramate [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2025.
  40. Wu H, Yang W, Guo T, Cai X, Ji L. Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications. BMC Med. 2025;23:398.
  41. Centers for Disease Control and Prevention. Breastfeeding special circumstances. cdc.gov/breastfeeding-special-circumstances/hcp/diet-micronutrients/maternal-diet.html. Accessed October 24, 2025.
  42. La Leche League International. Weight loss while breastfeeding. llli.org/breastfeeding-info/weight-loss-mothers/. Accessed October 24, 2025.
  43. Motuhifonua SK, Lin L, Alsweiler J, et al. Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. Cochrane Database Syst Rev. 2023;2:CD011507.
  44. Srivastava G, Kushner RF, Apovian CM, et al. Use of the historial weight trajectory to guide an obesity focused patient encounter. Endotext [Internet]. 2022.
  45. Bannuru RR; Professional Practice Committee. Weight stigma and bias: standards of care in overweight and obesity-2025. BMJ Open Diabetes Res Care. 2025;13(Suppl 1):e004962.
  46. Liraglutide [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; 2025.
  47. Semaglutide [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; 2025.
  48. Tirzepatide [prescribing information]. Indianapolis, IN: Eli Lilly and Company;2025.
  49. Lisdexamfetamine dimesylate [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America, Inc: 2025.
  50. Donato M, Capalbo A, Morizio E, et al. The role of lifestyle intervention in female fertility: A modifiable factor for preconception health. Nutrients. 2025;17:2101.
  51. Tchang BG, Mihai AC, Stefanski A, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity (Silver Spring). 2025;33:851-860.
  52. Liu L, Li Z, Ye W, et al. Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: A systematic review and meta-analysis. EClinicalMedicine. 2024;79:103020.
  53. Moon J, Koh G. Clinical evidence and mechanisms of high-protein diet-induced weight loss. J Obes Metab Syndr. 2020;29:166-173.
  54. Swift DL, Johannsen NM, Lavie CJ, et al. The role of exercise and physical activity in weight loss and maintenance. Prog Cardiovasc Dis. 2014;56:441-7.